Back to CVE records
Medium 6.7HealthcarePublished Aug 22, 2018

CVE-2018-14789In Philips' IntelliSpace Cardiovascular (ISCV) products (ISCV Version 3.1 or prior and Xcelera Version 4.1 or prior), an unquoted search path or element vulnerability has been identified, which may a…

Updated under an hour ago ()

Does this affect you?

It affects Philips IntelliSpace Cardiovascular (ISCV) products and 2 other products. Add what you run to find out whether that includes you.

EPSS puts the chance of exploitation in the next 30 days at 0.45%, higher than 37% of scored CVEs.

In Philips' IntelliSpace Cardiovascular (ISCV) products (ISCV Version 3.1 or prior and Xcelera Version 4.1 or prior), an unquoted search path or element vulnerability has been identified, which may allow an attacker to execute arbitrary code and escalate their level of privileges.

CVSS
6.7 MEDIUM (v3.1, NVD)CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:H/I:H/A:H
Weakness (CWE)
CWE-428
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
0.45% (percentile 37)
Assigned by
icscert
NVD analysis
Modified
Record last updated
Sep 16, 2024
First seen by InfoSec Signals
Oct 12, 2026

Affected products

Affected products
Philips IntelliSpace Cardiovascular (ISCV) products
philips:intellispace_cardiovascular_iscv_products (from the name)
IntelliSpace Cardiovascular, Version 3.1 or prior; Xcelera Version 4.1 or prior
CNA record
philips intellispace_cardiovascular
philips:intellispace_cardiovascular
through 3.1
NVD
philips xcelera
philips:xcelera
through 4.1
NVD

References

  • x-refsource-confirm, vendor-advisory
  • x-refsource-misc, third-party-advisory, us-government-resource

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.